Overview

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

Status:
Not yet recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

The addition of the SGLT2 inhibitor empagliflozin 10mg once daily to standard-of-care therapy administered early following acute myocardial infarction will result in a greater attenuation of adverse left ventricular remodelling, compared with matched placebo, in patients with left ventricular systolic dysfunction as a result of an acute myocardial infarction.

Phase:

Phase 4

Details

Lead Sponsor:

NHS Greater Glasgow and Clyde

Collaborator:

University of Glasgow

Treatments:

Empagliflozin